Ohtuvayre (ensifentrine), a drug approved in 2024 to treat chronic obstructive pulmonary disorder (COPD), is receiving high ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy ...

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium ... to relieve symptoms in adults with COPD. Bevespi, which is taken twice daily, is part of a new generation of medicines that ...

Inhaled corticosteroids are often used outside of the recommended indications in COPD. Researchers revealed a link between long-term use and several risks for new diagnoses. Adults with COPD who ...

Significantly greater composite adverse outcome rates seen for long- vs short-term inhaled corticosteroid use for prevalent, inception cohorts. HealthDay News — For patients with chronic ...

Inhalers may be prescribed to people who have a variety of health conditions both chronic and acute, including asthma, chronic obstructive pulmonary ... doing this daily or after a few usages ...

Background and goal: Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended as first-line treatment unless patients have asthma ...

Flare-ups in chronic obstructive pulmonary disease, the UK’s fourth leading cause of death, can be reduced by 20% by a combined triple inhaler, according to the results of a trial of more than 2,000 ...